Guangdong Hybribio Biotech Co (SZSE:300639) Operating Cash Flow per Share : ¥0.33 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co Operating Cash Flow per Share?

Guangdong Hybribio Biotech Co's operating cash flow per share for the three months ended in Mar. 2024 was ¥-0.09. Guangdong Hybribio Biotech Co's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.33.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Guangdong Hybribio Biotech Co was -83.30% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 3.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 53.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 35.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Guangdong Hybribio Biotech Co's Operating Cash Flow per Share or its related term are showing as below:

SZSE:300639' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 3.9 Med: 34.9 Max: 118.7
Current: 3.9

During the past 12 years, Guangdong Hybribio Biotech Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 118.70% per year. The lowest was 3.90% per year. And the median was 34.90% per year.

SZSE:300639's 3-Year OCF Growth Rate is ranked better than
56.82% of 176 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.5 vs SZSE:300639: 3.90

Guangdong Hybribio Biotech Co Operating Cash Flow per Share Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co Operating Cash Flow per Share Chart

Guangdong Hybribio Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.19

0.51

0.96

1.99

0.57

Guangdong Hybribio Biotech Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.16	-	0.18	0.23	-0.09

Competitive Comparison of Guangdong Hybribio Biotech Co's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, Guangdong Hybribio Biotech Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangdong Hybribio Biotech Co's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangdong Hybribio Biotech Co's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Guangdong Hybribio Biotech Co's Price-to-Operating-Cash-Flow falls into.

Guangdong Hybribio Biotech Co Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Guangdong Hybribio Biotech Co's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	319.598	/	561.889
	=	0.57

Guangdong Hybribio Biotech Co's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-64.051	/	717.739
	=	-0.09

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.33

Guangdong Hybribio Biotech Co Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000

Website

http://www.hybribio.cn

Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines